5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas

A 4-year-old develops chronic otitis on one side, then a sixth-nerve palsy. The “ear infection” is a parameningeal rhabdomyosarcoma of the middle ear and nasopharynx. A different 18-month-old has a grape-like vaginal mass that bleeds on diapers—botryoid embryonal rhabdomyosarcoma. A 12-year-old has a painless calf mass that is alveolar rhabdomyosarcoma with a FOXO1 fusion. Same family of tumors, three different CPHON maps. Rhabdomyosarcoma is the most common pediatric soft-tissue sarcoma. Questions test site, histology and fusion, grouping, VAC/VA-like drugs, and the nursing fallout of radiation and pelvic surgery—not a memorized catalog of every rare sarcoma name.

Sites that change risk

Think in anatomic neighborhoods, not “a lump somewhere.”

Head and neck, parameningeal. Parameningeal sites include nasopharynx, paranasal sinuses, middle ear, pterygopalatine and infratemporal fossae, and other locations that abut skull base and meninges. These tumors can invade the central nervous system, produce cranial-nerve palsies, and seed cerebrospinal fluid. Protocol workup commonly includes neuraxis imaging and, when indicated, lumbar puncture. Families should hear that this is not a simple ear or sinus infection even if that is how it started. Radiation is frequently part of local control. Nursing later means radiation dermatitis, mucositis, otitis, dental and salivary changes, and hearing surveillance when the field includes the ear.

Orbit. Orbital rhabdomyosarcoma classically presents with rapidly progressive proptosis and is a more favorable site on cooperative-group risk models. Vision preservation and careful radiation planning still matter, but the exam contrast is orbit versus parameningeal: do not lump every head-and-neck mass into the same prognosis speech.

Genitourinary. Botryoid (“grape-like”) tumors of vagina or bladder occur in infants and young children, usually embryonal histology, and can look like a vaginal foreign body or hematuria. Paratesticular tumors in boys are another genitourinary presentation. Bladder and prostate primaries are less favorable than vagina or paratestes on many schemas. After pelvic radiation or bladder surgery, teach bladder function: capacity, hematuria, continence, urinary tract infection, and the need for urology follow-up—not only “the mass is gone.”

Extremity and trunk. Limb and trunk tumors are more often alveolar, more often fusion-positive, and more often need intensive local control. A teenager’s painless extremity mass is not a sports bruise until imaging and biopsy say so. Regional nodes matter; sentinel or regional sampling follows protocol, not a casual clinic observation.

Embryonal versus alveolar, and FOXO1

Embryonal rhabdomyosarcoma is more common in younger children and at favorable head-neck and genitourinary sites. Alveolar rhabdomyosarcoma is more common in older children, extremities, and trunk. The molecular teaching point is FOXO1 fusion (PAX3-FOXO1 or PAX7-FOXO1). Fusion-positive alveolar disease is worse than typical embryonal disease and drives more intensive therapy and closer metastatic surveillance—lung, bone, marrow, and nodes depending on protocol. Fusion-negative tumors that look alveolar under the microscope may behave more like embryonal disease; the nurse’s teaching point is that fusion status changes risk, not that every alveolar-looking slide is identical.

Do not tell a family that “rhabdomyosarcoma is one chemotherapy recipe.” Site plus group plus fusion is the recipe.

IRS grouping and staging, without a museum of codes

Cooperative-group care still uses Intergroup Rhabdomyosarcoma Study clinical group plus site-based staging:

• Group I: complete resection, negative margins.
• Group II: microscopic residual disease or completely resected involved nodes.
• Group III: gross residual disease (biopsy only or incomplete resection)—the most common group at diagnosis because many sites cannot be fully excised up front.
• Group IV: distant metastases.

Staging additionally uses favorable versus unfavorable site, tumor size, nodes, and metastases. Favorable-site examples include orbit, non-parameningeal head and neck, and selected genitourinary sites such as vagina and paratestes. Unfavorable-site examples include parameningeal, bladder/prostate, extremity, trunk, and retroperitoneum. The CPHON job is not to recite every TNM box. It is to explain why a completely resected paratesticular embryonal tumor and a unresected parameningeal alveolar tumor will not share the same intensity, radiation plan, or fertility conversation.

Up-front mutilating surgery is not the goal. Biopsy, risk assignment, chemotherapy, then local control timed to the protocol is the usual sequence except when a small favorable tumor is already completely excised.

VAC/VA-like chemotherapy and radiation

Backbone therapy is VAC or reduced VA: vincristine, dactinomycin (actinomycin D), and cyclophosphamide, with radiation for residual disease, parameningeal sites, many alveolar tumors, and other protocol indications. Vincristine brings constipation, jaw pain, and foot drop—start a bowel regimen before the next weekly dose. Dactinomycin brings mucositis and radiosensitization; do not treat severe oral pain as “picky eating,” and watch skin in the radiation field for enhanced dermatitis. Cyclophosphamide brings myelosuppression, hemorrhagic cystitis risk (hydration and mesna when the protocol uses higher doses), and fertility injury, especially when pelvic radiation is added.

Radiation dermatitis in parameningeal fields involves face, scalp, ear canal, and mucous membranes. Teach gentle skin care, infection watch, and that “tanning” in the field is injury, not a cosmetic issue. After pelvic radiation or bladder/prostate surgery, ask about stream, urgency, incontinence, and sexual-function questions in adolescents in private. Offer fertility counseling before alkylators and pelvic radiation when the child’s developmental stage allows, and always with the parents of younger children so the record is not blank at survivorship clinic.

Fever-neutropenia still applies. A child with a parameningeal tumor and mucositis who spikes a fever is a two-problem emergency: infection plus a potential portal through damaged mucosa.

Non-rhabdomyosarcoma soft-tissue sarcomas, briefly

Not every pediatric soft-tissue mass is rhabdomyosarcoma. Synovial sarcoma typically appears in adolescents near large joints; it is one of the more chemotherapy-responsive non-rhabdomyosarcoma tumors but still needs expert local control. Infantile fibrosarcoma is a tumor of infants, often an extremity mass, classically associated with ETV6-NTRK3; NTRK-directed therapy is the modern teaching concept for unresectable or metastatic NTRK-fusion disease, rather than automatically copying a VAC rhabdomyosarcoma roadmap. Other non-rhabdomyosarcoma tumors (malignant peripheral nerve sheath tumor, undifferentiated sarcoma, and others) are managed on non-rhabdomyosarcoma protocols. The nursing trap is giving rhabdomyosarcoma discharge teaching to a family whose child is not on VAC.

A 3-month-old with a rapidly growing calf mass may have infantile fibrosarcoma, not alveolar rhabdomyosarcoma. A 15-year-old with a mass at the knee may have synovial sarcoma. Send both to a pediatric sarcoma center; do not start adult soft-tissue recipes or rhabdomyosarcoma VAC by habit.